But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.

BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.

What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.